The nation of Zimbabwe has declined a major US health deal worth $367m (£272m) over five years over Washington's request for sensitive data.
This move came to light following a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "skewed".
A government representative later stated that the US was requesting biological samples for scientific study and profit but was unwilling to guarantee the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for further dialogue to find a agreement suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
This development follows a similar situation in Kenya, where a high court blocked a related health funding agreement after legal challenges were raised about the security of Kenyans' medical information.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
As per reports, 16 African countries have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting frameworks already set up through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This system is intended to guarantee that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration could be arranged in a manner that honours the independence and interests of each country."
Health Experts Reaction
Medical experts expressed it acknowledged the official position, but recommended that negotiations should continue since a large portion of the nation's Aids initiatives depended on foreign aid.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal underscores the continuing tensions between receiving much-needed foreign assistance and protecting local interests in an increasingly data-driven world.